Discover the Impact of GEMTESA®: A Selective β3-Adrenergic Agonist for Effective OAB Treatment
Sponsored by Urovant
Program Description and Objectives:
This product theater will focus on a review of the overactive bladder treatment landscape and unmet medical needs followed by a clinical overview of GEMTESA®, A Selective β3-Adrenergic Agonist for Effective OAB Treatment
Faculty:
Prof. Christopher Chapple, BSc, MBBS, MD, FRCS (Urol), FEBU, FCSHK (Hon)
Prescribing Information